Wednesday, November 25, 2009

Abdominal Pain & Pain/Right/Left Upper Quadrant


Abdominal pain

Common causes of abdominal pain :

Abdominal wall pain

Pain arising from the abdominal wall is usually constant and aching.
Movement, prolonged standing, and pressure accentuate the discomfort and muscle spasm.

This kind of pain may arise from a disease of the muscle (myositis, trauma and hematoma, muscle strain), nerve disease (diabetic neuropathy, postherpetic neuralgia), or it could be referred pain from an internal abdominal organ.

Abdominal wall pain often presents with a dermatomic pattern.

Characteristically, it starts off as sharp initially and can become dull over time. Coughing, sneezing, or lifting heavy weights may increase the pain, while applying heat or changing positions may relieve abdominal wall pain.



Visceral pain


The best approach for visceral pain is according to location of pain and taking into account any associated symptoms to help guide the diagnosis.

Location is most easily categorized on the basis of embryologic origin. Pain located between the xiphoid process and the umbilicus originates in the foregut, which includes the distal esophagus, stomach, proximal duodenum, biliary tree, pancreas, and liver (although conditions of the liver usually do not cause chronic abdominal pain).

Pain in the periumbilical region arises from viscera of the midgut (eg, small intestine, appendix, ascending colon, proximal two thirds of the transverse colon).

Pain between the umbilicus and the symphysis pubis emanates from hindgut organs (eg, distal one third of the transverse colon, descending colon, rectosigmoid region).


1. The foregut




Pain in the epigastric area

The epigastrium is an area of the central abdomen lying just below the sternum.

Common causes are dyspepsia, peritonitis, pancreatitis, GI obstruction, gall bladder disease and peptic ulcer and ruptured aortic aneurysm. Other causes include inflammatory bowel syndrome, gastric cancer, referred pain (from a myocardial infarction, pleural disease or spinal disease) and psychosomatic diseases.

Pain in the right upper quadrant (hypochondrium)

Causes of right upper quadrant pain include liver diseases, gall bladder disease, lesions of the hepatic flexure of the colon (carcinoma, diverticulosis, ischaemic colitis, Chron's disease, atypical appendicitis or even constipation), renal diseases (pyelonephritis, nephro-lithiasis, hydronephrosis, renal carcinoma or other disease of the kidney or ureter, including obstruction of the urinary tract) or a dissecting aneurysm. Other causes include referred pain from the heart or a respiratory disease of the lower lobe of the lungs (lobar pneumonia or infarction from pulmonary embolism).

Many metabolic diseases can give the same picture including, diabetic ketoacidosis, Addisionian crisis, adrenal tuberculosis and metastatic carcinoma. Infections such as herpes zoster or a subphrenic abscess can also lead to pain in the right upper quadrant.

Pain in the left upper quadrant (hypochondrium)
Left upper quadrant pain is commonly associated with colonic diseases or splenic diseases. The spleen may be enlarged or may be the seat of an infarction. Diseases of the colon may include anything from distension of the splenic flexure of the colon as in cases of irritable bowel syndrome to colonic cancer.

2. The midgut

Pain in the periumbulical region
Causes of periumbulical pain include intestinal obstruction, mesenteric occlusion or enteritis.

3. The hindgut

Right lower quadrant pain

Pain in the right lower quadrant may be diffuse, as in early appendicitis, or crampy and nonradiating, as in ectopic pregnancy. Colon obstruction secondary to colon cancer, diverticulitis, and ureterolithiasis are common causes of pain in this area. Yersinia enterocolitica and Campylobacter sp., may mimic appendicitis and cause right lower quadrant pain, anorexia, low grade fever, and vomiting preceding the onset of diarrhea leading to a syndrome of mesenteric adenitis (lymph node enlargement) and terminal ileitis. The classic presentation of Crohn's disease is that of colicky right lower quadrant pain and diarrhea. Low-grade fever and weight loss are frequently present as well. High fever indicates a possible infectious complication (ie, abscess). Hematochezia occurs in a minority of patients, most often in those with colonic involvement.

In women right lower quadrant pain could be a manifestation of pelvic inflammatory disease, acute salpingitis, ectopic pregnancy, ovarian cysts, abscesses and tumors in addition to the causes listed above. Cancer of the cecum, ileal carcinoid, lymphosarcoma, systemic vasculitis, radiation enteritis, ileocecal TB, and ameboma should be excluded.

Left lower quadrant pain


Diverticulitis, inflammatory bowel disease, pelvic inflammatory disease, a kidney stone, endometriosis, ectopic pregnancy, and rupture of an ovarian cyst are common causes of abdominal pain in this area.

Pain in the hypogastrium and pelvis

Common causes of pain in this area include rectal disease (rectal cancer, proctitis); bladder disease (stones, cystitis, bladder cancer) and more importantly in females (salpingo-oopheritis, uterine cancer).


Pain in the costovertebral angle

This is usually attributed to renal causes (kidney stones, pyelonephritis and malignancy).

Clinical features of abdominal pain
Intensity and description of pain


Dull, gnawing sensation of mild to moderate severity can be caused by peptic ulcer disease.

Extremely intense pain of sudden onset may be the result of mesenteric ischemia or perforated peptic ulcer.

Renal colic refers to episodic pain with intervening pain-free intervals.

Biliary pain typically presents with constant, steady pain without intervening pain-free intervals.

Severe intensity and a "tearing" quality can be caused by a dissecting aneurysms causes pain.

Patients with postprandial pain, food avoidance, weight loss, and known atherosclerotic disease should be evaluated for mesenteric angina.

Time course
Sudden onset (over seconds to minutes) of abdominal pain suggests a catastrophic event such as a ruptured abdominal aneurysm, ruptured ectopic pregnancy, or perforated peptic ulcer.

Rapidly progressive (over 1-2 hours) pain is seen typically in pancreatitis, cholecystitis, diverticulitis, bowel obstruction, renal or biliary colic, and mesenteric ischemia.

Gradual (over several hours) pain that progresses more slowly is more typical of peptic ulcer disease, distal small bowel obstruction, appendicitis, pyelonephritis, pelvic inflammatory disease, and malignant neoplasm, although it may be seen with many of the diagnoses in the more rapidly progressive categories as well.

Pain occurring following the onset of vomiting often indicates a medical illness, whereas pain that precedes vomiting often indicates a surgical illness. Persistence of pain for over 6 hours after acute onset has a high likelihood of a surgical cause and requires admission for observation.

Aggravating or alleviating factors
Pain relieved by antacids suggests peptic ulcer disease or esophagitis.

Pain worsened by movement suggests peritonitis, whereas constant movement by the patient in an attempt to find a comfortable position is commonly seen in bowel obstruction and renal colic.

Patients with partial relief by leaning forward, and aggravation by lying supine suggests a retroperitoneal process (such as pancreatitis) commonly find

Pain relieved by defecation may suggest a colonic source.

Patients with postprandial pain, food avoidance, weight loss, and known atherosclerotic disease should be evaluated for chronic intestinal ischemia (mesenteric angina) or intermittent intestinal obstruction (from internal or abdominal wall hernias, adhesions, or Crohn's disease).

Pain that occurs at approximately monthly intervals should raise the suspicion of endometriosis or Mittelschmerz.

Physical examination
Vital signs


Tachycardia & hypotension: Vital signs may show tachycardia and hypotension indicative of intraabdominal hemorrhage or septic shock.


Fever: The fever of appendicitis, diverticulitis, and cholecystitis is typically low grade, whereas high fevers are seen in cases of cholangitis, urinary tract infections, pelvic inflammatory disease, or perforation of a viscus with frank peritonitis.

Inspection

Abdominal distention: Abdominal distention may suggest bowel obstruction or the presence of ascites.


Scaphoid abdomen: A scaphoid, tense abdomen is seen in cases of peritonitis.

Auscultation

Auscultation of the abdomen should be performed before palpation or percussion so as not to interfere with the interpretation of bowel sounds.

Absence of bowel sounds: Absence of bowel sounds is a sign of diffuse peritonitis.


Hyperactive bowel sounds: Intermittent hyperactive bowel sounds occurring concurrently with worsening of pain suggest a bowel obstruction. High-pitched hyperactive bowel sounds may also be seen in gastroenteritis.


Succussion splash: The presence of a succussion splash suggests gastric outlet obstruction.

Percussion

Tenderness on percussion: Percussion of the abdomen allows assessment of the presence of peritonitis. Pain produced by light tapping indicates inflammation of the parietal peritoneum. This pain may also be elicited by asking the patient to cough or by gently agitating the gurney upon which the patient is lying.


Tympany: A distended abdomen with tympany upon percussion suggests a bowel obstruction.

Palpation

Tightening (rigidity) of the abdominal wall musculature occurs as a reflexive response to peritoneal inflammation (voluntary guarding refers to tightness or rigidity of the abdomen that relaxes when the patient takes a deep breath, whereas involuntary guarding refers to rigidity of the abdominal wall musculature that does not relax in response to deep inspiration). Involuntary guarding indicates peritoneal inflammation.

Tenderness over McBurney's point should be considered very strong evidence of appendicitis.

Cholecystitis and salpingitis are often well localized as well, and salpingitis may be confused with appendicitis.

Patients with an unimpressive abdominal examination and complaints of severe, worsening pain should be suspected of having mesenteric infarction.

Murphy's sign refers to pain produced by deep inspiration during palpation of the right subcostal area and suggests acute cholecystitis.

Pain produced by lightly punching the costovertebral angle ("punch tenderness") is often present in pyelonephritis.

Carnett's test refers to the response of pain when the patient tenses the abdominal wall muscles by raising their head off the examination table. Worsening of pain during this maneuver suggests an abdominal wall source whereas improvement in the pain suggests a visceral origin.

The iliopsoas sign refers to pain produced by passive extension of the leg and suggests a psoas abscess.

The obturator sign refers to pain produced by rotation of the thigh in a flexed position.

A rectal examination can reveal focal tenderness from an intraabdominal abscess or appendicitis.

A pelvic examination is mandatory in female patients to look for evidence of salpingitis or adnexal masses.

The inguinal and femoral canals, umbilicus, and surgical scars should be evaluated for the presence of incarcerating hernias.

Once a cause is suspected the appropriate diagnostic procedure for the provisional diagnosis is selected.

Diagnosis
If the picture is obscure then the following important points and causes should be taken into account:

Ruptured ectopic pregnancy in females


Dissecting aortic aneurysm: Absence of tenderness and rigidity in the presence of continuous, diffuse pain in a patient likely to have vascular disease is quite characteristic of occlusion of the superior mesenteric artery. Abdominal pain with radiation to the sacral region, flank, or genitalia should always signal the possible presence of a rupturing abdominal aortic aneurysm. This pain may persist over a period of several days before rupture and collapse occur.
Peritoneal pain: Rigidity, rebound tenderness, fever and leucocytosis

Metabolic causes
Familial mediterranean fever
Diabetic ketoacidosis

Irritable bowel syndrome: Is the commonest cause of abdominal pain and should always be kept in mind.

If the cause of abdominal pain is still unclear, investigations that can be requested include:

Lab work

X-rays (supine, erect, lateral view)

Ultrasound

CAT scan

Laparoscopy

Operation vs. watchful waiting

Chronic abdominal pain

Chronic pain usually has persisted for 3 to 6 months and is affecting the patient's activities of daily living. Often, the diagnosis can be made through history taking.

Chronic epigastric pain can be caused by peptic ulcer, chronic pancreatitis, GERD, dyspepsia, gall bladder disease.

Chronic lower abdominal pain can be caused by irritable bowel syndrome, inflammatory bowel disease, cancer. Right lower quadrant fullness and pain or perianal disease may indicate Crohn's disease.

Less common causes include causes in the abdominal wall, fibromyalgia, hernia, referred pain, metabolic disorders (porphyria, chronic renal failure, and Addison's disease) and psychological disorders.

The evaluation of chronic abdominal pain in a patient younger than 50 years old typically begins with ruling out the presence of alarm symptoms (weight loss, gastrointestinal bleeding, anemia, fever, or frequent nocturnal symptoms).

If no alarm symptoms are present and the patient has altered bowel habits then evaluation for irritable bowel syndrome is considered. This my include a CBC, TSH and electrolyte levels, and examination with flexible sigmoidoscopy.

Those with alarm symptoms or age above 50 years old may require a referral to a gastroenterologist.
____________
____________
In Case You Missed It
_____________
______________
Also very interesting stuff, sort of fun to read._
____________
______________
_____________
_____________
But remember a little knowledge can be dangerous.
The internet can be a great place to learn, but its not
a replacement for seeing your Physician.
If you search long enough you sure will come up with
a diagnoses which will be 99% inaccurate .
After I read this post I swear I had twelve
different failing organs . Life is fun, huh?


Replace Biopsies in Diagnosing Diseased Tissue?

Vibrating Technology Promises to Replace Biopsies in Diagnosing Diseased Tissue


Magnetic resonance elastography (MRE), developed at Minnesota's Mayo Clinic, uses low frequency sound waves to determine whether tissues and organs are too stiff, a sign of trouble
By Larry Greenemeier



Biopsies, although invasive and unpleasant, are typically the best way to diagnose the health of human tissue, especially the liver. A group of researchers and physicians at the Mayo Clinic in Rochester, Minn., is hoping to change this through a relatively new approach known as magnetic resonance elastography (MRE), which they developed to measure the stiffness or elasticity of tissue and organs without the need for a scalpel.

Through MRE, a device placed on the body near the tissue being tested uses vibration to generate low frequency sound waves that pass through organs that have varying degrees of elasticity. These data are measured and analyzed to determine when tissue is stiffer than it should be, often a sign that it is unhealthy.

In addition to biopsies, doctors often make disease diagnoses by feeling the skin and tissue surrounding an organ with their fingers to determine the level of elasticity (a process called palpation). The goal with MRE is to eliminate the need for painful biopsies and offer a sort of virtual palpation that could even be used to examine organs including the heart and the brain, which doctors cannot reach without major surgery.

Thus far, the most common application of MRE since it was first used at the Mayo Clinic in 2007 has been diagnosing liver disease. The demand for a better way of diagnosing this disease is greater than most people think, says Richard Ehman, a Mayo Graduate School professor of radiology and leader of the Mayo Clinic team that developed MRE. Nearly 170 million people worldwide have hepatitis C infections and one quarter of those cases can lead to liver disease that leaves the organ scarred and otherwise damaged, he says, adding, "The latest estimate is that in the U.S. 5 million people have hepatitis C infections and many people don't even know it."

More than 15 years ago, Ehman began experimenting with mechanically produced seismic waves—called shear waves—that could travel through human tissue. As these waves pass through the body, they displace tissue by a matter of a micron or less. Ehman and his colleagues modified a magnetic resonance imaging (MRI) system to be able to detect these incredibly subtle changes and found that by applying a mathematical algorithm to the data produced by the scan researchers could generate an image that quantified the stiffness or elasticity of an organ. "I was inspired by the power of palpation as a diagnostic tool for physicians," he says. "Simple touch can find things that highly sophisticated equipment can miss."

It took the ensuing decade and a half to develop the technology that could make MRE practical in the human body. GE Healthcare on Monday introduced its MR-Touch device, the first commercial application of MRE technology, which the company has licensed from the Mayo Clinic.

The MRE sequence takes about 15 seconds and can be performed at the end of a standard 45-minute MRI liver exam. If doctors could more easily diagnose liver fibrosis (scarring caused by the hepatitis C virus) or cirrhosis (characterized by the replacement of liver tissue with fibrous scar tissue), they could "treat, halt and in many cases reverse the disease," Ehman says. The technology, he adds, also holds out the possibility of early detection of liver cancer.



More On:Vitamin D Boosts TX of Chronic HCV

Vitamin D Boosts Treatment of Chronic Hepatitis C
Hepatitis C is an inflammation of the liver caused by the spherical, enveloped single-strand RNA virus.
The World Health Organization estimated 170 million individuals worldwide are infected with the hepatitis C virus (HCV). In the U.S., HCV accounts for 20% of all cases of acute (severe and of short duration) hepatitis, an estimated 30,000 new acute infections, and 8000 to 10,000 deaths annually.
Chronic (long term) hepatitis C is predominately transmitted by percutaneous (through the skin) exposure to infected blood.

The treatment with most promising results is a combination of pegylated interferon alfa (Pegasys, PEG-Intron) and the antiviral drug, ribavirin (Vitrazole). Interferon alfa is a protein which the human body produces naturally as a defense response to viral infections. Pegylation describes a chemical process that makes the interferon last longer in the body.
Interferon increases the potency of ribavirin in the treatment of HCV.

Adding a daily dose of Vitamin D to the regimen of pegylated interferon-alfa 2 and ribavirin might increase the response rates, according to an abstract which was presented at the Liver Meeting 2009, the 60th Annual Meeting of the American Association of the Study of Liver Disease.

"This preliminary study confirms the benefit of adding Vitamin D to conventional antiviral therapy in patients with chronic hepatitis C". states lead investigator, Saif M. Abu-Mouch, MD, from the Department of Hepatology, Hillel Yaffe Medical Center in Hadera, Israel. (1)

In the study, 58 patients, the control group, who were diagnosed with HCV, were randomly assigned to the protocol of peginterferon-alfa 2b 1.5 ug/kg once per week and ribavirin 1000 to 2000 mg daily. Thirty-one patients received the same treatment plus Vitamin D 1000 to 4000 IU daily.
By the fourth week of treatment, a rapid virological (pertaining to viruses) response was seen in 44% of the patients who received Vitamin D and in 18% of the control group. At the twelfth week of treatment, 96% of the group who received the addition of Vitamin D and 48% of the control group were HCV RNA negative.

"The study is surprising and promising because Vitamin D is something very easy to use and there is no toxicity. It's also interesting that the group treated with Vitamin D had more severe disease than the control group. I think this can be considered a strong result from a small study", commented Laurent Tsakins, MD. who was an attendee of the meeting. (1)

1) http://www.medscape/

Maryann Gromisch is a registered nurse, who has working on the medical, surgical, and critical care units of a hospital, and with a gastroenterologist in a private practice setting.
_______________________
In Case You Missed It
_______________________________________

Tuesday, November 24, 2009

Off Topic/ Enjoy


Perched on the edge of a waterfall in Katmai National Park, Alaska, a mother grizzly bear demonstrates the art of salmon catching to her cubs


Grizzly Bears Catching Salmon - Nature's Great Events: The Great Salmon Run - BBC One





This huge Griffon Vulture was feeding on a carcass when the aggressive fox attacked.


The duel was captured on camera, in Southern Bulgaria, by 30 year old wildlife photographer and tour guide Mladen Vasilev


An astonishing thing to see - Near Oxford - England. This was filmed at an RSPB reserve called Otmoor. It is the most remarkable thing I have ever seen - and as a video camerman I have seen some pretty amazing things.



Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients


SUMMARY: Sustained response to interferon-based treatment for chronic hepatitis C virus (HCV) infection can slow the rate of progression to hepatic decompensation, liver cancer, and liver-related death, according to 2 studies presented this month at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) in Boston.


V. Di Marco and colleagues from Italy (abstract 345) assessed whether antiviral therapy that leads to clearance of HCV RNA at an advanced stage of disease improves long-term outcomes for patients with cirrhosis (scarring) of the liver.


Compensated cirrhosis means the liver is badly damaged, but can still carry out most of its essential functions; decompensated disease occurs when the liver can no longer do so. As liver disease progresses, accumulating scar tissue impedes the flow of blood through the organ, resulting in symptoms such as portal hypertension, abdominal fluid accumulation (ascites), and enlarged, weakened blood vessels (varices) in the esophagus and stomach.

The investigators followed a prospective cohort of 358 patients with compensated HCV-related cirrhosis, with or without esophageal varices. Study participants were treated with pegylated interferon alfa-2b (PegIntron), at does of 1 or 1.5 mg/kg/week, plus 1000-1200 mg/day weight-adjusted ribavirin.


Participants were enrolled starting in 2001.

All had more than 24 months of follow-up, allowing evaluation of sustained virological response (SVR), or continued undetectable HCV viral load 6 months after completion of treatment. Participants underwent ultrasound prior to therapy and every 6 months to assess presence of esophageal varices.

Results


Overall, 79 patients (22%) achieved SVR.
During a median 40 months of follow-up, 3 patients who achieved SVR developed decompensation, compared with 76 non-sustained-responders.
1 patient with SVR and 78 without SVR developed hepatocellular carcinoma (HCC).
In a multivariate analysis, the following factors were independently associated to hepatic decompensation:

Lack of SVR: odd ratio (OR) 4.36, or more than 4 times higher risk;
Presence of esophageal varices: OR 3.73;
Child Pugh score of 6: OR 2.79;
Platelet count below 90,000 cells/mm3: OR 1.94.

The following factors were independently associated with development of HCC:

Lack of SVR: OR 10.10, or more than 10 times higher risk;
Platelet count below 90,000 cells/mm3: OR 2.97;
Male sex: OR 2.90.
Liver-related mortality was independently associated with:

Lack of SVR: OR 8.59;
Platelet count below 90,000 cells/mm3: OR 2.85.
Based on these findings, the investigators concluded, "SVR after antiviral treatment obtains a meaningful reduction in the rate of hepatic decompensation, of HCC, and of liver-related deaths in patients with compensated HCV cirrhosis, regardless of the presence of portal hypertension at the time of starting treatment."

Esophageal Varices


In a related study, S. Bruno and colleagues (abstract 281), also from Italy, conducted a study to assess the cumulative incidence and predictors associated with development of esophageal varices and to evaluate the impact of antiviral therapy and emergence of HCC on varice occurrence.


The researchers studied 218 consecutive patients with compensated HCV-related cirrhosis but free of esophageal varices when they enrolled between 1989 and 1992. During a median follow-up period of 11.4 years, 149 participants received interferon-based antiviral therapy. Ultrasound and upper endoscopy were performed at intervals of 6 months and 3 years intervals, respectively.

Results


34 treated patients (23%) achieved SVR, and none of them developed esophageal varices.
Of the 184 patients who were either not treated or did not achieve SVR, 67 developed esophageal varices.
In a multivariate analysis, development of esophageal varices was significantly associated with:

HCV genotype 1b: hazard ratio (HR) OR 2.40;
Elevated baseline MELD score: HR 1.20 per 1-point increase.
51 of the untreated or non-responder patients who were free of varices at the last endoscopy developed HCC.

The 10 year cumulative incidence of esophageal varice detection were as follows:

17% among patients without HCC;
67% among all patients who developed HCC;
64% among patients who developed HCC without previous or concurrent decompensation.
After adjustment for other confounding factors, having HCC was associated with an approximately 3-fold increased risk of esophageal varice development (HR 2.87).
"SVR achievement prevents esophageal varice development in the long-term," the researchers concluded. "In addition to genotype 1b and MELD score at baseline, HCC occurrence is the main determinant associated with esophageal varice emergence. As a result, the current guidelines for esophageal varice surveillance should be revised accordingly."
11/24/09


References
V Di Marco, V Calvaruso, S De Lisi, and others. HCV clearance after PEG IFN plus RBV improves the course of HCV cirrhosis regardless of portal hypertension. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston. October 30-November 1, 2009. Abstract 345.
S Bruno, A Crosignani, C Facciotto, and others. The impact of sustained virologic response and hepatocellular carcinoma occurrence on the de-novo development of esophageal varices in compensated, HCV-induced cirrhosis. A long term prospective study. 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston. October 30-November 1, 2009. Abstract 281.

Treatment rates for hepatitis C virus declining, say researchers

Treatment rates for hepatitis C virus declining, say researchers
24. November 2009 01:27

Research suggests lack of diagnosis is primary barrier to treatment
Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates appear to be declining, in part because only half of the patients know they are infected. If this disturbing trend continues, by 2030 less than 15% of liver-related deaths from HCV will be prevented by antiviral therapy. This study, the first to analyze nationwide practice patterns for HCV treatment, is published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

HCV is a common blood-borne infection that slowly damages the liver by causing inflammation of liver tissue, which can lead to cirrhosis, chronic liver disease, and liver cancer. In the U.S., HCV is a major public health burden and the leading cause of liver transplantation. According to the Centers for Disease Control and Prevention (CDC) 8,000-12,000 deaths occur each year due to HCV. While the incidence of new infections has declined, past studies point to a twofold to fourfold increase in death over the next 20 years due to widespread cases with longstanding infection.

Michael Volk, M.D., M.Sc., and colleagues obtained data of new patient prescriptions for pegylated interferon alpha-2a and -2b, sold under the brand names Pegasys and Peg Intron, respectively, and filled between 2002- 2007. Results of the prescription audit showed there were 126,000 new prescriptions for pegylated interferon products in 2002 and by 2007 that figured declined to 83,000 prescriptions. Researchers project fewer than 1.4 million patients would be treated cumulatively with antiviral medication by 2030 if the downward trend continued.

To further understand the decrease in antiviral therapy, researchers investigated treatment decisions using data from the National Health and Nutrition Evaluation Survey (NHANES) Hepatitis C Follow-Up Questionnaire. They discovered that 49% of respondents were previously unaware of their diagnosis and 24% of patients with HCV were not recommended for treatment by their physician. Approximately 9% of those surveyed did not follow up with their doctors regarding their HCV, 8% refused treatment, and only 12% received treatment. "It is concerning that half of all people with hepatitis C in the U.S. are unaware of their diagnosis," said Dr. Volk. "Even with the development of new and better medications on the horizon, such medications will have less than optimal impact unless more patients are diagnosed and referred for treatment."

The study further suggested that barriers to HCV screening may be attributed to lack of health insurance, limited access to standard medical care, and lower priority for testing by primary care doctors. "This is unfortunate," added Dr. Volk, "since young patients who don't go to the doctor often may be the best candidates for antiviral therapy." The authors conclude that increased public health efforts are needed to improve access to antiviral therapy, and recommend further research of health services delivery and quality of care for HCV patients.


Source: Wiley-Blackwell

Monday, November 23, 2009

Why Hepatitis B Hits Men Harder Than Women

Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.
Their study has been published online in ACS' Journal of Proteome Research, a monthly publication. Shuhan Sun, Fang Wang and colleagues note that chronic hepatitis B seems to progress and cause liver damage faster in men, with men the main victims of the virus's most serious complications -- cirrhosis and liver cancer.
Men infected with HBV also are 6 times more likely than women to develop a chronic form of the disease. About 400 million people worldwide have chronic hepatitis B, including a form that is highly infectious and can be transmitted through blood, saliva, and sexual contact.
In experiments with laboratory mice, the scientists found abnormal forms of apolipoprotein A-I (Apo A-I), a protein involved in fighting inflammation, in the livers of infected male mice but not infected females.
They then identified abnormal forms of these Apo A-I proteins in blood of men infected with HBV, but not in women. In addition to explaining the gender differences, the proteins may provide important markers for tracking the progression of hepatitis B, the scientists suggest.
Article: "An altered pattern of liver apolipoprotein A-I is implicated in male chronic hepatitis B progression" http://pubs.acs.org/stoken/presspac/presspac/full/10.1021/pr900593r
Source: Michael Bernstein American Chemical Society